Tomásia Oliveira de Holanda Monteiro Frezatti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tomásia Oliveira de Holanda Monteiro Frezatti has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Américo Ceiki Sakamoto
Department of Neurosciences and Behaviour Sciences Universidade de São Paulo, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto Ribeirão Preto São Paulo Brazil
4 shared publications - Ricardo Lutzky Saute
Department of Neurosciences and Behaviour Sciences Universidade de São Paulo, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto Ribeirão Preto, São Paulo Brazil
2 shared publications - Vanessa Daccach Marques
Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Departamento de Neurociências e Ciências do Comportamento, Ribeirão Preto SP, Brazil
2 shared publications - Antonio Carlos dos Santos
Department of Neurosciences and Behaviour Sciences Universidade de São Paulo, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto Ribeirão Preto, São Paulo Brazil
1 shared publication Antônio Carlos dos Santos
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto Universidade de São Paulo, Ribeirão Preto, São Paulo Brazil
1 shared publicationFrederico Nakane Nakano
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto Universidade de São Paulo, Ribeirão Preto, São Paulo Brazil
1 shared publication
Latest Publications
- Open Access
- 8 October 2026
- Published by Wiley in Epileptic Disorders
Pragmatic screening for autoimmune‐associated epilepsy in drug‐resistant epilepsy of unknown etiology in resource‐limited settings: A hypothesis‐generating study
Objective: To evaluate the feasibility of investigating autoimmune etiology in adults with drug‐resistant epilepsy (DRE) of unknown origin in resource‐limited settings and to develop a pragmatic, hypothesis‐generating screening approach to guide autoantibody testing. Methods: A prospective observational study including adults with DRE of unknown etiology was conducted at a tertiary epilepsy center in Brazil. All patients underwent standardized assessment including inflammatory and autoimmunity markers, brain magnetic resonance imaging (MRI), electroencephalography (EEG), cerebrospinal fluid (CSF) analysis, and application of the APE2 and ACES scores. Clinical, laboratory, and imaging findings were analyzed in the context of published autoimmune‐associated epilepsy (AAE) profiles to inform a pragmatic screening strategy. Results: Twenty‐six patients (46.2% female; median epilepsy duration: 18.5 years) were included. EEG findings were nonspecific. Six patients developed mesial temporal abnormalities on follow‐up MRI. CSF protein elevation was observed in 37.5%, oligoclonal bands in 13.6%, and elevated IgG index in 18.2%. Antinuclear antibodies were detected in 26.9%. APE2 score ≥ 4 was present in 57.7%, while ACES score ≥ 2 occurred in 11.5%. Due to limited access to antibody testing, only one patient underwent CSF autoantibody analysis, confirming high‐titer anti‐GAD65. Based on integrated clinical, laboratory, and imaging findings, a pragmatic screening algorithm was proposed to prioritize candidates for autoantibody testing. Significance: In resource‐limited settings, systematic use of accessible clinical and laboratory markers may help identify patients with higher pre‐test probability of AAE. A pragmatic screening approach may improve diagnostic efficiency and support individualized decision‐making when comprehensive antibody testing is not readily available.
- 8 October 2026
- Published by Wiley in Epileptic Disorders
Open AccessPragmatic screening for autoimmune‐associated epilepsy in drug‐resistant epilepsy of unknown etiology in resource‐limited settings: A hypothesis‐generating study
Objective: To evaluate the feasibility of investigating autoimmune etiology in adults with drug‐resistant epilepsy (DRE) of unknown origin in resource‐limited settings and to develop a pragmatic, hypothesis‐generating screening approach to guide autoantibody testing. Methods: A prospective observational study including adults with DRE of unknown etiology was conducted at a tertiary epilepsy center in Brazil. All patients underwent standardized assessment including inflammatory and autoimmunity markers, brain magnetic resonance imaging (MRI), electroencephalography (EEG), cerebrospinal fluid (CSF) analysis, and application of the APE2 and ACES scores. Clinical, laboratory, and imaging findings were analyzed in the context of published autoimmune‐associated epilepsy (AAE) profiles to inform a pragmatic screening strategy. Results: Twenty‐six patients (46.2% female; median epilepsy duration: 18.5 years) were included. EEG findings were nonspecific. Six patients developed mesial temporal abnormalities on follow‐up MRI. CSF protein elevation was observed in 37.5%, oligoclonal bands in 13.6%, and elevated IgG index in 18.2%. Antinuclear antibodies were detected in 26.9%. APE2 score ≥ 4 was present in 57.7%, while ACES score ≥ 2 occurred in 11.5%. Due to limited access to antibody testing, only one patient underwent CSF autoantibody analysis, confirming high‐titer anti‐GAD65. Based on integrated clinical, laboratory, and imaging findings, a pragmatic screening algorithm was proposed to prioritize candidates for autoantibody testing. Significance: In resource‐limited settings, systematic use of accessible clinical and laboratory markers may help identify patients with higher pre‐test probability of AAE. A pragmatic screening approach may improve diagnostic efficiency and support individualized decision‐making when comprehensive antibody testing is not readily available.
- Open Access
- 8 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (14) , 5349
From Acute Symptomatic Seizures to Post-Stroke Epilepsy: A Narrative Review of Diagnosis and Management
Stroke is a major cause of acquired epilepsy in adults, particularly in older individuals. However, seizures after stroke should not be regarded as a single clinical entity. Acute symptomatic seizures (ASyS) occur within the first seven days after stroke and are considered provoked events, whereas remote symptomatic seizures carry a higher recurrence risk and may fulfill the practical definition of post-stroke epilepsy (PSE). This narrative review provides a clinically oriented synthesis of current evidence on definitions, epidemiology, pathophysiology, risk factors, predictive scores, EEG and biomarker-based risk stratification, seizure prevention, and antiseizure medication (ASM) management. Current evidence does not support routine primary antiseizure medication prophylaxis for all stroke patients. In contrast, documented clinical or electrographic seizures require appropriate treatment, and established PSE often requires long-term individualized therapy. Predictive tools may help guide surveillance, EEG indication, counseling, and follow-up, but should not be used as automatic triggers for prophylactic treatment. ASM choice should account for seizure type, age, comorbidities, cognitive and psychiatric vulnerability, drug interactions, and secondary vascular prevention. Future research should focus on validated biomarkers and preventive strategies capable of modifying epileptogenesis after stroke.
- 8 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (14) , 5349
Open AccessFrom Acute Symptomatic Seizures to Post-Stroke Epilepsy: A Narrative Review of Diagnosis and Management
Stroke is a major cause of acquired epilepsy in adults, particularly in older individuals. However, seizures after stroke should not be regarded as a single clinical entity. Acute symptomatic seizures (ASyS) occur within the first seven days after stroke and are considered provoked events, whereas remote symptomatic seizures carry a higher recurrence risk and may fulfill the practical definition of post-stroke epilepsy (PSE). This narrative review provides a clinically oriented synthesis of current evidence on definitions, epidemiology, pathophysiology, risk factors, predictive scores, EEG and biomarker-based risk stratification, seizure prevention, and antiseizure medication (ASM) management. Current evidence does not support routine primary antiseizure medication prophylaxis for all stroke patients. In contrast, documented clinical or electrographic seizures require appropriate treatment, and established PSE often requires long-term individualized therapy. Predictive tools may help guide surveillance, EEG indication, counseling, and follow-up, but should not be used as automatic triggers for prophylactic treatment. ASM choice should account for seizure type, age, comorbidities, cognitive and psychiatric vulnerability, drug interactions, and secondary vascular prevention. Future research should focus on validated biomarkers and preventive strategies capable of modifying epileptogenesis after stroke.
- 18 June 2026
- Published by Wiley in Epileptic Disorders
- Vol. 28 (5) , 1723-1726
Clinical and imaging evolution of anti‐ GAD65 ‐associated epilepsy
- 18 June 2026
- Published by Wiley in Epileptic Disorders
- Vol. 28 (5) , 1723-1726
Clinical and imaging evolution of anti‐ GAD65 ‐associated epilepsy
- Open Access
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (07) , 001-012
Autoimmune-associated epilepsy: definitions and diagnosis – a narrative review
Autoimmune-associated epilepsy (AAE) is an increasingly-recognized condition in which seizures result from immune-mediated mechanisms, such as Rasmussen's encephalitis and antibody-associated epilepsies. Its timely identification may enable more efficacious therapy and improve outcomes. The current paper aims to provide a clinically-oriented review of AAE, focusing on clinical identification, use of diagnostic scoring systems, and immunological testing strategies. Antibody-associated epilepsy encompasses a broad spectrum of presentations, from postencephalitic epilepsy to isolated drug-resistant temporal-lobe epilepsy. Neuronal-surface autoantibodies (such as anti-N-methyl-D-aspartate receptor (anti-NMDAR), anti- leucine-rich glioma-inactivated protein 1 (anti-LGI1), anti-CASPR2) and intracellular antibodies (such as anti-GAD65) are variably associated with pathogenesis and chronicity. Clinical scoring systems (such as Antibody Prevalence in Epilepsy and Encephalopathy - APE2, Antibody Contributing to Focal Epilepsy Signs and Symptoms - ACES, ntibody Prevalence in Epilepsy before Surgery - APES, Antibody in Drug-Resistant Temporal Lobe Epilepsy - ARTE and ‘Obvious’ Indications for Neural Antibody Testing in Epilepsy or Seizures - ONES) are helpful in selecting patients for autoantibody testing. A comprehensive workup includes magnetic resonance imaging (MRI) scans, prolonged electroencephalographic (EEG) monitoring, cerebrospinal fluid (CSF) analysis, and combined serum/CSF antibody panels. Testing methodology and antibody type must be carefully interpreted in the light of clinical context. In low-resource settings, cost-effective testing strategies and clinical-screening tools are crucial to optimize the diagnostic yield. Early clinical suspicion, guided use of diagnostic scores, and appropriate immunological investigation are central to manage AAE. Recognizing AAE as a distinct diagnostic category is essential to improve care and guide immunotherapeutic decisions.
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (07) , 001-012
Open AccessAutoimmune-associated epilepsy: definitions and diagnosis – a narrative review
Autoimmune-associated epilepsy (AAE) is an increasingly-recognized condition in which seizures result from immune-mediated mechanisms, such as Rasmussen's encephalitis and antibody-associated epilepsies. Its timely identification may enable more efficacious therapy and improve outcomes. The current paper aims to provide a clinically-oriented review of AAE, focusing on clinical identification, use of diagnostic scoring systems, and immunological testing strategies. Antibody-associated epilepsy encompasses a broad spectrum of presentations, from postencephalitic epilepsy to isolated drug-resistant temporal-lobe epilepsy. Neuronal-surface autoantibodies (such as anti-N-methyl-D-aspartate receptor (anti-NMDAR), anti- leucine-rich glioma-inactivated protein 1 (anti-LGI1), anti-CASPR2) and intracellular antibodies (such as anti-GAD65) are variably associated with pathogenesis and chronicity. Clinical scoring systems (such as Antibody Prevalence in Epilepsy and Encephalopathy - APE2, Antibody Contributing to Focal Epilepsy Signs and Symptoms - ACES, ntibody Prevalence in Epilepsy before Surgery - APES, Antibody in Drug-Resistant Temporal Lobe Epilepsy - ARTE and ‘Obvious’ Indications for Neural Antibody Testing in Epilepsy or Seizures - ONES) are helpful in selecting patients for autoantibody testing. A comprehensive workup includes magnetic resonance imaging (MRI) scans, prolonged electroencephalographic (EEG) monitoring, cerebrospinal fluid (CSF) analysis, and combined serum/CSF antibody panels. Testing methodology and antibody type must be carefully interpreted in the light of clinical context. In low-resource settings, cost-effective testing strategies and clinical-screening tools are crucial to optimize the diagnostic yield. Early clinical suspicion, guided use of diagnostic scores, and appropriate immunological investigation are central to manage AAE. Recognizing AAE as a distinct diagnostic category is essential to improve care and guide immunotherapeutic decisions.